ArticleJNCI cancer spectrum2026
Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).The journal of liquid biopsy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo enhance risk stratification in metastatic castrate-resistant prostate cancer (mCRPC), we developed clinical and integrated clinico-genomic prognostic nomograms combining clinical prognostic factors with copy number alteration-based risk scores (RSs) in circulating tumor DNA (ctDNA) and metastatic tissue to predict 1-, 2-, and 3-year overall survival (OS) probabilities.
methodsA clinical prognostic nomogram was developed from publicly accessed Yale University Open Data Access (YODA) data-sciences project (N = 1088 patients). A second publicly available independent dataset (N = 82) with an 11-gene prognostic RS developed concurrently obtained ctDNA and matched metastatic tissue specimens (gains: AR, MYC, COL22A1, PIK3CA, PIK3CB, NOTCH1; losses: TMPRSS2, NCOR1, ZBTB18, TP53, NKX3-1) was used to develop an integrated clinico-genomic survival nomogram. Independent predictors for survival were identified in each dataset using univariate and multivariate Cox proportional hazard. Multivariate regression coefficients with statistical significance (P < .05) were used to develop prognostic nomograms to estimate 1-, 2- and 3-year OS probabilities. Nomogram performances were assessed using time-dependent area under curves (t-AUCs). All analyses were conducted in RStudio (v4.1.2).
resultsThe YODA dataset t-AUCs for the prognostic nomogram for estimating OS at 1, 2, and 3 years were 0.74, 0.70, and 0.74. In the independent second dataset, the integrated clinico-genomic prognostic nomogram was observed to have higher t-AUCs for predicting 3-year mCRPC survival at 0.807 compared with 0.714 using clinical factors alone.
conclusionsAn integrated clinico-genomic nomogram with ctDNA RSs achieved the highest t-AUC for 3-year survival in mCRPC and may enable precision in identification of poor-prognosis subgroups based on somatic alterations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.